NCT06762925

Brief Summary

This study aims to validate the accuracy and clinical value of METTL3 as a biomarker for predicting immune therapy response in patients with urinary tract tumors through observational studies.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
450

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2025

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 21, 2024

Completed
2 months until next milestone

First Posted

Study publicly available on registry

January 8, 2025

Completed
22 days until next milestone

Study Start

First participant enrolled

January 30, 2025

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2026

Completed
Last Updated

January 8, 2025

Status Verified

December 1, 2024

Enrollment Period

1.3 years

First QC Date

November 21, 2024

Last Update Submit

January 7, 2025

Conditions

Bladder CancerProstate CancerKidney Cancer

Outcome Measures

Primary Outcomes (1)

  • The expression levels of METTL3 and ANGPTL2

    About a year and a half

Study Arms (3)

Bladder Cancer

Other: No Interventions

Prostate Cancer

Other: No Interventions

Kidney Cancer

Other: No Interventions

Interventions

No InterventionsOTHER

No Interventions

Bladder CancerKidney CancerProstate Cancer

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with urological tumors

You may qualify if:

  • Patients diagnosed with urinary system tumors through pathological examination;
  • Meet specific clinical stages and surgical treatment standards;
  • Intraoperative tissue resection meets the sample testing standards;
  • The patient is willing to participate in the study and sign an informed consent form.

You may not qualify if:

  • Not meeting the specific clinical stage and not receiving surgical treatment;
  • Abnormal mental behavior;
  • Intellectual disability;
  • Age under 18 years old or over 75 years old;
  • Low understanding and communication skills.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Urinary Bladder NeoplasmsProstatic NeoplasmsKidney Neoplasms

Condition Hierarchy (Ancestors)

Urologic NeoplasmsUrogenital NeoplasmsNeoplasms by SiteNeoplasmsFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesUrinary Bladder DiseasesUrologic DiseasesMale Urogenital DiseasesGenital Neoplasms, MaleGenital Diseases, MaleGenital DiseasesProstatic DiseasesKidney Diseases

Central Study Contacts

shihao shang

CONTACT

17868780610shang225@hotmail.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Target Duration
3 Months
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 21, 2024

First Posted

January 8, 2025

Study Start

January 30, 2025

Primary Completion

June 1, 2026

Study Completion

June 1, 2026

Last Updated

January 8, 2025

Record last verified: 2024-12